Lanpeng Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lanpeng Lu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hui Cheng
Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China
6 shared publications - Hui Ding
Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China
6 shared publications - Jianzhong Lu
Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, China
6 shared publications - Junqiang Tian
Department of Urology, Lanzhou University Second Hospital, Lanzhou, China
6 shared publications - Lanlan Li
Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, Gansu, China
6 shared publications - Shanhui Liu
Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China
6 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
TAK-901 targets the inhibition of EGFR and activates the FOXO pathway to induce apoptosis in bladder cancer cells, related to Figure 5
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
TAK-901 targets the inhibition of EGFR and activates the FOXO pathway to induce apoptosis in bladder cancer cells, related to Figure 5
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
Bladder cancer is the most prevalent malignancy of the urinary tract, characterized by an unfavorable prognosis, elevated rates of recurrence, and a lack of targeted therapeutic approaches. In this research, we evaluated the efficacy of TAK-901, a specific inhibitor targeting Aurora kinase, and elucidated the anticancer mechanisms in bladder cancer. TAK-901 exhibited a dose-dependent inhibition of proliferation, colony formation, and migration, as well as the induction of apoptosis in T24 and UMUC-3 cells. Additionally, bladder cancer cells underwent cell-cycle arrest at the G2–M-phase when exposed to TAK-901. Mechanistic studies revealed that the targeted inhibition of epidermal growth factor receptor (EGFR) by TAK-901 affected AKT and forkhead box class O3a (FOXO3a) phosphorylation, leading to the activation of FOXO-dependent transcriptional activity, which subsequently triggered apoptotic pathways by inducing BIM expression. Furthermore, our study demonstrated that TAK-901 attenuated tumor growth in the UMUC-3–luciferase xenograft model and significantly reduced Ki-67 expression in tumor tissues. Finally, we propose a novel treatment strategy involving the synergistic inhibition of bladder cancer cell growth by combining TAK-901 with afatinib. Our research strongly suggests that Aurora A and Aurora B are promising epigenetic therapeutic targets in bladder cancer. Furthermore, TAK-901 can function as a targeted kinase inhibitor and EGFR inhibitor for the treatment of bladder cancer by activating the FOXO signaling pathway, which induces apoptosis in bladder cancer cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
Bladder cancer is the most prevalent malignancy of the urinary tract, characterized by an unfavorable prognosis, elevated rates of recurrence, and a lack of targeted therapeutic approaches. In this research, we evaluated the efficacy of TAK-901, a specific inhibitor targeting Aurora kinase, and elucidated the anticancer mechanisms in bladder cancer. TAK-901 exhibited a dose-dependent inhibition of proliferation, colony formation, and migration, as well as the induction of apoptosis in T24 and UMUC-3 cells. Additionally, bladder cancer cells underwent cell-cycle arrest at the G2–M-phase when exposed to TAK-901. Mechanistic studies revealed that the targeted inhibition of epidermal growth factor receptor (EGFR) by TAK-901 affected AKT and forkhead box class O3a (FOXO3a) phosphorylation, leading to the activation of FOXO-dependent transcriptional activity, which subsequently triggered apoptotic pathways by inducing BIM expression. Furthermore, our study demonstrated that TAK-901 attenuated tumor growth in the UMUC-3–luciferase xenograft model and significantly reduced Ki-67 expression in tumor tissues. Finally, we propose a novel treatment strategy involving the synergistic inhibition of bladder cancer cell growth by combining TAK-901 with afatinib. Our research strongly suggests that Aurora A and Aurora B are promising epigenetic therapeutic targets in bladder cancer. Furthermore, TAK-901 can function as a targeted kinase inhibitor and EGFR inhibitor for the treatment of bladder cancer by activating the FOXO signaling pathway, which induces apoptosis in bladder cancer cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
The combination of TAK-901 and Afatinib demonstrates synergistic inhibition of bladder cancer cell growth.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
The combination of TAK-901 and Afatinib demonstrates synergistic inhibition of bladder cancer cell growth.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
TAK-901 suppresses bladder cancer cell growth in vitro, related to Figure 2
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
TAK-901 suppresses bladder cancer cell growth in vitro, related to Figure 2
- 21 April 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (8) , OF1-OF13
TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
Bladder cancer is the most prevalent malignancy of the urinary tract, characterized by an unfavorable prognosis, elevated rates of recurrence, and a lack of targeted therapeutic approaches. In this research, we evaluated the efficacy of TAK-901, a specific inhibitor targeting Aurora kinase, and elucidated the anticancer mechanisms in bladder cancer. TAK-901 exhibited a dose-dependent inhibition of proliferation, colony formation, and migration, as well as the induction of apoptosis in T24 and UMUC-3 cells. Additionally, bladder cancer cells underwent cell-cycle arrest at the G2–M-phase when exposed to TAK-901. Mechanistic studies revealed that the targeted inhibition of epidermal growth factor receptor (EGFR) by TAK-901 affected AKT and forkhead box class O3a (FOXO3a) phosphorylation, leading to the activation of FOXO-dependent transcriptional activity, which subsequently triggered apoptotic pathways by inducing BIM expression. Furthermore, our study demonstrated that TAK-901 attenuated tumor growth in the UMUC-3–luciferase xenograft model and significantly reduced Ki-67 expression in tumor tissues. Finally, we propose a novel treatment strategy involving the synergistic inhibition of bladder cancer cell growth by combining TAK-901 with afatinib. Our research strongly suggests that Aurora A and Aurora B are promising epigenetic therapeutic targets in bladder cancer. Furthermore, TAK-901 can function as a targeted kinase inhibitor and EGFR inhibitor for the treatment of bladder cancer by activating the FOXO signaling pathway, which induces apoptosis in bladder cancer cells.
- 21 April 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (8) , OF1-OF13
TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer
Bladder cancer is the most prevalent malignancy of the urinary tract, characterized by an unfavorable prognosis, elevated rates of recurrence, and a lack of targeted therapeutic approaches. In this research, we evaluated the efficacy of TAK-901, a specific inhibitor targeting Aurora kinase, and elucidated the anticancer mechanisms in bladder cancer. TAK-901 exhibited a dose-dependent inhibition of proliferation, colony formation, and migration, as well as the induction of apoptosis in T24 and UMUC-3 cells. Additionally, bladder cancer cells underwent cell-cycle arrest at the G2–M-phase when exposed to TAK-901. Mechanistic studies revealed that the targeted inhibition of epidermal growth factor receptor (EGFR) by TAK-901 affected AKT and forkhead box class O3a (FOXO3a) phosphorylation, leading to the activation of FOXO-dependent transcriptional activity, which subsequently triggered apoptotic pathways by inducing BIM expression. Furthermore, our study demonstrated that TAK-901 attenuated tumor growth in the UMUC-3–luciferase xenograft model and significantly reduced Ki-67 expression in tumor tissues. Finally, we propose a novel treatment strategy involving the synergistic inhibition of bladder cancer cell growth by combining TAK-901 with afatinib. Our research strongly suggests that Aurora A and Aurora B are promising epigenetic therapeutic targets in bladder cancer. Furthermore, TAK-901 can function as a targeted kinase inhibitor and EGFR inhibitor for the treatment of bladder cancer by activating the FOXO signaling pathway, which induces apoptosis in bladder cancer cells.